Cardiovascular and metabolic effects of CPAP in obese obstructive sleep apnoea patients

European Respiratory Journal

Volumn 31, Issue 1, 2008, Pages 223-225

  Teramoto, S ^a   Yamaguchi, Y ^a   Yamamoto, H ^a   Hanaoka, Y ^a   Ishii, M ^a   Hibi, S ^a   Ishii, T ^a   Kume, H ^a   Ouchi, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE; CARDIOVASCULAR EFFECT; DISEASE SEVERITY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LETTER; METABOLISM; OBESITY; POSITIVE END EXPIRATORY PRESSURE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; SLEEP APNEA SYNDROME; SYMPATHETIC TONE; BODY COMPOSITION; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLIC SYNDROME X; NOTE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TIME; TREATMENT OUTCOME;

PLACEBO;

BODY COMPOSITION; CARDIOVASCULAR SYSTEM; CONTINUOUS POSITIVE AIRWAY PRESSURE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PLACEBOS; SEX FACTORS; SLEEP APNEA, OBSTRUCTIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 45849123554     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00105707     Document Type: Letter

References (10)

1. Coughlin SR, Mawdsley L, Mugarza JA, Wilding JP, Calverley PM. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007; 29: 720-727.
2. Teramoto S, Ohga E, Ouchi Y. Obstructive sleep apnoea. Lancet 1999; 354: 1213-1214.
3. Teramoto S, Kume H, Yamaguchi Y, et al. Improvement of endothelial function with allopurinol may occur in selected patients with OSA: effect of age and sex. Eur Respir J 2007; 29: 216-217.
4. Sasanabe R, Banno K, Otake K, et al. Metabolic syndrome in Japanese patients with obstructive sleep apnoea syndrome. Hypertens Res 2006; 29: 315-322.
5. Phillips CL, Yang Q, Williams A, et al. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnoea. J Sleep Res 2007; 16: 217-225.
6. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnoea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005; 9: 211-224.
7. Teramoto S, Yamamoto H, Yamaguchi Y, Namba R, Ouchi Y. Obstructive sleep apnoea causes systemic inflammation and metabolic syndrome. Chest 2005; 127: 1074-1075.
8. Teramoto S, Yamamoto H, Ouchi Y. Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnoea syndrome. Circulation 2003; 107: E40-0.
9. Sharma SK, Kumpawat S, Goel A, Banga A, Ramakrishnan L, Chaturvedi P. Obesity, and not obstructive sleep apnoea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 2007; 8: 12-17.
10. Lindberg E, Berne C, Elmasry A, Hedner J, Janson C. CPAP treatment of a population-based sample - what are the benefits and the treatment compliance? Sleep Med 2006; 7: 553-560.